Last $0.06 USD
Change Today -0.0004 / -0.61%
Volume 10.2K
WNDM On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

wound management technologie (WNDM) Snapshot

Open
$0.06
Previous Close
$0.06
Day High
$0.06
Day Low
$0.06
52 Week High
03/3/14 - $0.13
52 Week Low
11/21/14 - $0.03
Market Cap
5.3M
Average Volume 10 Days
75.9K
EPS TTM
$-0.05
Shares Outstanding
88.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for WOUND MANAGEMENT TECHNOLOGIE (WNDM)

Related News

No related news articles were found.

wound management technologie (WNDM) Related Businessweek News

No Related Businessweek News Found

wound management technologie (WNDM) Details

Wound Management Technologies, Inc. develops, markets, and distributes collagen-based wound care products to physicians, clinics, and hospitals in the United States. The company offers CellerateRX, a medical device for use on acute and chronic wounds in gel and powder form. It also holds patents for a resorbable bone wax and delivery system for orthopedic bone void fillers. The company was formerly known as MB Software Corporation and changed its name to Wound Management Technologies, Inc. in May 2008. Wound Management Technologies, Inc. was founded in 1982 and is based in Addison, Texas.

9 Employees
Last Reported Date: 04/30/14
Founded in 1982

wound management technologie (WNDM) Top Compensated Officers

Chairman of The Board and Chief Executive Off...
Total Annual Compensation: $125.0K
President
Total Annual Compensation: $32.5K
President of Wound Care Innovations LLC
Total Annual Compensation: $120.0K
Compensation as of Fiscal Year 2013.

wound management technologie (WNDM) Key Developments

Wound Management Technologies, Inc. Announces Financial Results for the Third Quarter and Nine Months Ended September 30, 2014

Wound Management Technologies, Inc. announced financial results for the third quarter and nine months ended September 30, 2014. For the quarter, the company generated revenues for the three months ended September 30, 2014, of $679,122, as compared to revenues of $472,753 for the three months ended September 30, 2013, or 44% increase in revenues. Net loss for the three months ended September 30, 2014 of $671,007, as compared to a net loss of $1,687,496 for the three months ended September 30, 2013. The Company was able to reduce net loss in 2014 by increasing sales and significantly reducing interest and debt related expenses. For the nine months, the company generated revenues for the nine months ended September 30, 2014, of $1,905,766, as compared to revenues of $1,263,170 for the nine months ended September 30, 2013, or a 51% increase in revenues. Net loss for the nine months ended September 30, 2014 of $1,992,894, as compared to a net loss of $2,662,187 for the nine months ended September 30, 2013. The company was able to reduce net loss in 2014 by increasing sales and significantly reducing interest and debt related expenses.

Wound Management Technologies Appoints Ronald Goode and Jeffrey Lewis to the Board of Directors

Wound Management Technologies, Inc. announced that the Company appointed Ronald Goode and Jeffrey Lewis to the Board of Directors. Ronald Goode, Ph.D., has an extensive background in healthcare and brings a wealth of knowledge from a management and clinical perspective. Dr. Goode has served as President and CEO of Unimed Pharmaceuticals and eXegenics and held key management positions at Pfizer Pharmaceuticals and G.D. Searle & Co. He is currently the President and CEO of the Goode Group. Jeffrey Lewis currently serves as President of the Institute for Healthcare Innovation. Mr. Lewis spent many years working in Congress and is the former President of the Heinz Family Philanthropies. He was an instrumental player in building healthcare solutions for both public and private employers.

Wound Management Technologies, Inc. Approves Amendment to its Articles of Incorporation

Wound Management Technologies, Inc. approved the amendment to the company's Articles of Incorporation to increase the authorized shares of common stock of the Company from 100,000,000 to 250,000,000 and authorized the filing, within the next twelve months of an additional amendment to the company's Articles of Incorporation effecting a 1-for-10 reverse split of the company's common stock in the annual meeting of stockholders held on September 3, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WNDM:US $0.06 USD -0.0004

WNDM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for WNDM.
View Industry Companies
 

Industry Analysis

WNDM

Industry Average

Valuation WNDM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WOUND MANAGEMENT TECHNOLOGIE, please visit www.wmgtech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.